1.2-Bis-<4-amidino-anilino>-ethan | 109642-01-5

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 1.2-Bis-<4-amidino-anilino>-ethan
• 英文别名: EBAB；4,4'-(1,2-ethanediyldiimino)bis-benzenecarboximidamide；4-[2-(4-Carbamimidoylanilino)ethylamino]benzenecarboximidamide
• CAS: 109642-01-5
• 化学式: C₁₆H₂₀N₆
• 分子量: 296.375
• InChiKey: XEJKYNUTJGTYGY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  22
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  124
• 氢给体数：
  6
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  1.2-Bis-<4-amidino-anilino>-ethan 在 盐酸 作用下， 以 二氯甲烷 为溶剂， 生成 4,4'-(1,2-ethanediyldiimino)bis-benzenecarboximidamide dihydrochloride
  参考文献：
  名称：

  1,2-Ethane bis-1-amino-4-benzamidine is active against several brain insult and seizure challenges through anti-NMDA mechanisms targeting the 3H-TCP binding site and antioxidant action

  摘要：

  Five bis-benzamidines were screened towards murine magnesium deficiency-dependent audiogenic seizures, unravelling two compounds with efficacious doses 50 (ED50) less than 10 mg/kg. They were also screened against maximal electroshock and subcutaneous pentylenetetrazole-induced seizures, and explored for superoxide -scavenging activity. 1,2-Ethane bis-1-amino-4-benzamidine (EBAB) was selected and evaluated in 6 Hz seizure test (ED50 = 49 mg/kg) and at 4 mu g/kg in focal cerebral ibotenate poisoning in pups (sizes of both white and grey matter wounds were halved). EBAB was further tested on NMDA-induced seizures in mice (ED50 = 6 mg/kg) and on H-3-TC-binding to a rodent cerebral preparation (IC50 = 1.4 mu M). Taken as a whole, present data emphasise the suitability of bis-benzamidines as templates for designing brain protective compounds. (c) 2010 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2010.03.044
• 作为产物：
  描述：

  4,4'-(1,2-ethanediyldiimino)bis-(N-hydroxybenzenecarboximidamide) 在 10% palladium on carbon 、 甲酸铵 、 溶剂黄146 作用下， 反应 2.0h， 生成 1.2-Bis-<4-amidino-anilino>-ethan
  参考文献：
  名称：

  1,2-Ethane bis-1-amino-4-benzamidine is active against several brain insult and seizure challenges through anti-NMDA mechanisms targeting the 3H-TCP binding site and antioxidant action

  摘要：

  Five bis-benzamidines were screened towards murine magnesium deficiency-dependent audiogenic seizures, unravelling two compounds with efficacious doses 50 (ED50) less than 10 mg/kg. They were also screened against maximal electroshock and subcutaneous pentylenetetrazole-induced seizures, and explored for superoxide -scavenging activity. 1,2-Ethane bis-1-amino-4-benzamidine (EBAB) was selected and evaluated in 6 Hz seizure test (ED50 = 49 mg/kg) and at 4 mu g/kg in focal cerebral ibotenate poisoning in pups (sizes of both white and grey matter wounds were halved). EBAB was further tested on NMDA-induced seizures in mice (ED50 = 6 mg/kg) and on H-3-TC-binding to a rodent cerebral preparation (IC50 = 1.4 mu M). Taken as a whole, present data emphasise the suitability of bis-benzamidines as templates for designing brain protective compounds. (c) 2010 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2010.03.044

文献信息

• Bisbenzamidine derivatives for use as antioxidant
  申请人：Université de Mons-Hainaut

  公开号：EP2116236A1

  公开（公告）日：2009-11-11

  The invention is directed to the use of bisbenzamidine compounds of Formula (I) as antioxidant and as neuroprotective agents, wherein R1, R2, R3, R4 and L have the meaning defined in the claims.

  本发明涉及将式（I）的双苯基胍化合物用作抗氧化剂和神经保护剂，其中R1、R2、R3、R4和L的含义如权利要求所定义。
• Amidine derivatives for treating amyloidosis
  申请人：Chalifour J. Robert

  公开号：US20070021483A1

  公开（公告）日：2007-01-25

  The present invention relates to the use of amidine compounds in the treatment of amyloid-related diseases. In particular, the invention relates to a method of treating or preventing an amyloid-related disease in a subject comprising administering to the subject a therapeutic amount of an amidine compound. Among the compounds for use according to the invention are those according to the following Formula, such that, when administered, amyloid fibril formation, neurodegeneration, or cellular toxicity is reduced or inhibited:

  本发明涉及在治疗与淀粉样相关疾病中使用氨基脲类化合物。特别地，本发明涉及一种治疗或预防受试者淀粉样相关疾病的方法，包括向受试者施用治疗剂量的氨基脲类化合物。根据本发明使用的化合物包括以下化学式的化合物，当施用时，可减少或抑制淀粉样纤维形成、神经退行性或细胞毒性：
• 1,2-Ethane bis-1-amino-4-benzamidine is active against several brain insult and seizure challenges through anti-NMDA mechanisms targeting the 3H-TCP binding site and antioxidant action
  作者：Joseph Vamecq、Pierre Maurois、Nicole Pages、Pierre Bac、James P. Stables、Pierre Gressens、Dimitri Stanicki、Jean Jacques Vanden Eynde

  DOI：10.1016/j.ejmech.2010.03.044

  日期：2010.7

  Five bis-benzamidines were screened towards murine magnesium deficiency-dependent audiogenic seizures, unravelling two compounds with efficacious doses 50 (ED50) less than 10 mg/kg. They were also screened against maximal electroshock and subcutaneous pentylenetetrazole-induced seizures, and explored for superoxide -scavenging activity. 1,2-Ethane bis-1-amino-4-benzamidine (EBAB) was selected and evaluated in 6 Hz seizure test (ED50 = 49 mg/kg) and at 4 mu g/kg in focal cerebral ibotenate poisoning in pups (sizes of both white and grey matter wounds were halved). EBAB was further tested on NMDA-induced seizures in mice (ED50 = 6 mg/kg) and on H-3-TC-binding to a rodent cerebral preparation (IC50 = 1.4 mu M). Taken as a whole, present data emphasise the suitability of bis-benzamidines as templates for designing brain protective compounds. (c) 2010 Elsevier Masson SAS. All rights reserved.